-
平臺編號：bio-49424
-
國際編號：ATCC VR-2031
-
拉丁屬名： Vaccinia virus deposited as Vaccinia virus
-
規(guī)格：frozen
-
用途：ATCC原裝進口
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
Vaccinia virus deposited as Vaccinia virus
ATCC? Number:VR-2031?
Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus deposited as Vaccinia virus, Orthopoxvirus
Strain: Vtk-79
Depositors: New York State Department of Health
Biosafety Level:2
Shipped: frozen
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Host Organism : HeLa cells (ATCCCCL-75); CV-1 cells (ATCCCCL-70)
Incubation : Duration: 5 days
Effect : Yes, in vitro effects: Cytopathic effects in tissue culture
Comments : Vaccination recommended for lab staff manipulating vaccinia, monkeypox, or cowpox viruses (CDC/NIH Biosafety in Microbiological and Biomedical Laboratories, 4th ed, 1999 - stock no. 017-040-00547-4). A thymidine kinase negative variant of the S-variant of vaccinia strain WR. A thymidine kinase negative (TK-) mutant of the S-variant of vaccinia virus strain WR. Plasmids can be introduced into this mutant by in vivo recombination. [13130] Prepared by: E. Paoletti Isolated from an S-variant vaccinia population subjected to strong selective pressure by growing in cells in the presence of 5-bromo-2'-deoxyuridine. [13130]
References : 13123: Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986 13130: Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988 13139: Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520
Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus deposited as Vaccinia virus, Orthopoxvirus
Strain: Vtk-79
Depositors: New York State Department of Health
Biosafety Level:2
Shipped: frozen
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Host Organism : HeLa cells (ATCCCCL-75); CV-1 cells (ATCCCCL-70)
Incubation : Duration: 5 days
Effect : Yes, in vitro effects: Cytopathic effects in tissue culture
Comments : Vaccination recommended for lab staff manipulating vaccinia, monkeypox, or cowpox viruses (CDC/NIH Biosafety in Microbiological and Biomedical Laboratories, 4th ed, 1999 - stock no. 017-040-00547-4). A thymidine kinase negative variant of the S-variant of vaccinia strain WR. A thymidine kinase negative (TK-) mutant of the S-variant of vaccinia virus strain WR. Plasmids can be introduced into this mutant by in vivo recombination. [13130] Prepared by: E. Paoletti Isolated from an S-variant vaccinia population subjected to strong selective pressure by growing in cells in the presence of 5-bromo-2'-deoxyuridine. [13130]
References : 13123: Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986 13130: Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988 13139: Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520
